A groundbreaking study has shed new light on the potential benefits of estrogen-only hormone therapy in reducing the risk of Alzheimer's disease in women. The research, which analyzed data from over 21,000 participants, found that women who underwent estrogen-only hormone therapy later in life were less likely to develop dementia and showed fewer signs of Alzheimer's disease in their brains.
Key Insights
The study's key findings include a significant link between estrogen-only hormone therapy and a lower risk of dementia, with hormone therapy use associated with 39% lower odds of a dementia diagnosis and 35% lower odds of Alzheimer's-related brain changes at autopsy. These findings suggest that estrogen-only hormone therapy may play a crucial role in reducing the risk of Alzheimer's disease in women, and highlight the need for further research into the potential benefits and risks of this treatment approach.










